A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity

NCT06184568 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

349

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes
Obesity

Interventions

DRUG: IBI362
DRUG: Semaglutide

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.